BETAISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND A MONOAMINE OXIDASE INHIBITOR, FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF VERTIGO IN A SUBJECT
CY1126201T1Undetermined Publication Date: 2026-07-31INTRABIO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CY20231100343T
- Authority / Receiving Office
- CY · CY
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-07-20
- Filing Date
- 2023-07-19
- Publication Date
- 2026-07-31
- Estimated Expiration
- 2043-07-19
Abstract
A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to a subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
Need to check novelty before this filing date? Find Prior Art